MedTrace Logo

Apelin in Willis Ekbom Disease

NCT02264600 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2014-10-15

No results posted yet for this study

Summary

The purpose of this study is to assess apelin level in patients with Willis-Ekbom Disease (WED) as known Restless Legs Syndrome (RLS). Cardiovascular complications of WED have been reported in recent studies. Increased oxidative stress is thought to play an important role in cardiovascular complications of WED patients. Apelin is a novel described antioxidant bioactive peptide. The investigators hypothesize that patients with WED have lower plasma apelin level than healthy subjects based on presence of oxidative stress of WED.

Conditions

  • Restless Legs Syndrome

Sponsors & Collaborators

  • Acibadem University

    lead OTHER

Principal Investigators

  • Murat Aksu, Prof. Dr. · Acibadem University Faculty of Medicine, School of Electroneurophysiology

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-02-28
Completion
2015-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02264600 on ClinicalTrials.gov